Abstract: Described herein are abuse deterrent controlled release oral pharmaceutical compositions comprising and methods for making the same. In particular, an abuse deterrent controlled release oral pharmaceutical composition comprising a soft capsule and an abuse deterrent controlled release matrix comprising an active pharmaceutical ingredient are described.
Type:
Application
Filed:
August 11, 2020
Publication date:
November 26, 2020
Inventors:
Saujanya Gosangari, Justin Hughey, Tatyana Dyakonov, George VAMVAKAS, Aqeel A. FATMI
Abstract: The present invention provides a lipid nanoparticle composition and a pharmaceutical composition thereof used in treating a hematoproliferative disorder. Specifically, the lipid nanoparticle composition may include cytarabine, an anthracycline, and lipid nanoparticles, wherein cytarabine and the anthracycline are co-encapsulated in the lipid nanoparticles, the lipid nanoparticles comprise a charged lipid stabilizer, and the effective mean particle size of the lipid nanoparticles is less than 400 nm.
Abstract: The present invention generally relates to compositions and methods for delivering a vaccine. The compositions and methods disclosed herein are particularly useful in making prophylactic and therapeutic vaccines.
Abstract: The present invention provides a nucleic acid-containing lipid nanoparticle comprising an analog of a fatty acid ester of glycerol, and a nucleic acid, wherein the analog is not hydrolyzable by a lipase.
Abstract: Embodiments of the present disclosure pertain to delivery agents for delivering one or more active agents to desired cells (e.g., adipose stromal cells). The delivery agents generally include: (1) a particle; (2) one or more active agents carried by the particle; and (3) a targeting agent associated with the particle, where the targeting agent directs the delivery agent to the desired cells. Additional embodiments of the present disclosure pertain to methods for delivering active agents to adipose stromal cells through the use of the aforementioned delivery agents. In some embodiments, the methods include a step of associating the adipose stromal cells with the delivery agent such that the associating results in the delivery of the active agents into the adipose stromal cells. The associating can occur by administering the delivery agent to a subject for the treatment or prevention of obesity and related disorder or diseases in the subject.
Type:
Application
Filed:
February 21, 2019
Publication date:
November 26, 2020
Applicants:
Texas Tech University System, University of Tennessee research Foundation
Inventors:
Shu Wang, Ling Zhao, Zhaoyang Fan, Yujiao Zu
Abstract: A method of delivering nicotine to treat dyskinesia, such as Levodopa induced dyskinesia (LID), includes delivering a first dose of nicotine to a patient using a transdermal delivery device and delivering a second dose of nicotine to the patient using the transdermal delivery device. The first and second doses are timed such that a refractory period between peak plasma levels of nicotine in the patient prevents desensitization of nicotinic acetylcholine receptors while reducing symptoms of LID.
Type:
Application
Filed:
January 5, 2018
Publication date:
November 26, 2020
Inventors:
Anubhav ARORA, Navdeep KAUR, Guy DiPIERRO, Patrick H. RUANE, Ravinder D. PAMNANI
Abstract: A method of treating, reducing or preventing bacterial infection in a wound, the method comprising: applying a film on the wound, the film including a biodegradable polymer with bacteriophages dispersed therein, wherein the polymer is a poly (ester amide urea).
Type:
Application
Filed:
August 13, 2020
Publication date:
November 26, 2020
Inventors:
Nancy Tawil, Ramaz Katsarava, David Tugushi, Vakhtang Beridze
Abstract: Disclosed herein are methods for treating juvenile onset neurological conditions, such as autism (ASD), intellectual disability, or epilepsy, with an inhibitor of N-methyl-D-aspartate receptor (NMDAR). The inhibitor may be NitroSynapsin or a derivative thereof.
Abstract: The present invention discloses a method for preventing the formation of calcified deposits or inside an isolated biological matrix comprising the step of contacting said isolated biological matrix with a solution comprising a mixture of phenolic compounds.
Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
Type:
Application
Filed:
August 10, 2020
Publication date:
November 26, 2020
Inventors:
Geoffrey GUY, Stephen WRIGHT, Orrin DEVINSKY
Abstract: A deacetylnemorone abietane diterpenoid is utilized in the prevention of growth and development of pathogenic cells, e.g., cancer cells. The deacetylnemorone can have the following structure: or a tautomer there of in which R1, R2, and R3 are independently selected from —H, C1-10 alkyl, C1-10 alkoxy, C1-10 alkenyl, C1-10 alkenoxy, —OH, —OAc, —CHO, -Ph, —OC6H5, —OC6H4OH, —COC6H5, —OCONH2, —OCONHCH3, —OCOC6H4NH2, —NH2, or ?O. The deacetylnemorone shows efficacy in treatment and prevention of a wide range of cancer types, as well as other neoplastic diseases as a chemo-preventative, a primary or secondary cytotoxic agent, a sensitizer for other therapies, or one component of a combinatorial treatment.
Type:
Application
Filed:
August 5, 2020
Publication date:
November 26, 2020
Inventors:
EHSAN JABBARZADEH, WESLEY F. TAYLOR, SARA ESLAMBOLCHI MOGHADAM
Abstract: The present disclosure is directed to methods for treating a neuropsychiatric disorder associated with expression of autoantibodies to ionotropic glutamate receptor, NMD A 2A (GiuN2A), expression of anti-double-stranded (ds) DNA antibodies that cross react with one or more subunits of the NMD A receptor, or a mutation in the ionotropic glutamate receptor NMD A type subunit 2A (GRIN2A) gene. The methods involve administering a memantine, or a pharmaceutically acceptable salt thereof, to a subject suffering from a neuropsychiatric disorder associated with expression of GluN2A or a mutation in the GRIN2A gene.
Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
Type:
Application
Filed:
January 27, 2020
Publication date:
November 26, 2020
Inventors:
Todd Brady, Scott Young, William A. Kinney, Kenneth J. Mandell
Abstract: Disclosed herein are methods of inhibiting tumor growth or producing tumor regression in a subject having a drug-resistant estrogen receptor alpha positive cancer or a mutant estrogen receptor alpha positive cancer. The methods entail administering to the subject a therapeutically effective amount of RAD1901 having the structure: or a salt or solvate thereof.
Abstract: Disclosed herein are methods of treating subjects suffering from estrogen receptor positive cancer of the brain by administering a selective estrogen receptor degrader (SERM). Also disclosed are methods of treating a cancer that is resistant to an estrogen receptor modulator by administering a SERM.
Type:
Application
Filed:
August 6, 2020
Publication date:
November 26, 2020
Inventors:
Suzanne E. Wardell, Erik R. Nelson, Donald P. McDonnell
Abstract: The present invention relates to a combination formulation containing metformin for treating non-insulin-dependent diabetes and an HMG-CoA reductase inhibitor for treating dyslipidemia. The present invention provides a combination formulation and a method for preparing the combination formulation, wherein the combination formulation contains metformin and an HMG-CoA reductase inhibitor.
Type:
Application
Filed:
August 10, 2020
Publication date:
November 26, 2020
Inventors:
Kwi Man KANG, Young Joon PARK, Jun Hong PARK, Ji Eun LEE, Seok Kee YOON, Yu Jeong KIM, Tack Oon OH, Tae Keun CHO
Abstract: A method for modulating metabolism is provided which includes the step of providing a consumable composition including an extract containing a compound of Formula Ito a subject in need thereof thereby modulating the subject's metabolism and addressing the underlying pathogenesis of metabolic disorders, such as nonalcoholic fatty liver disease, nonalcoholic steatohepatitis and type II diabetes mellitus.
Abstract: Oral pharmaceutical compositions of sodium oxybate having improved pharmacokinetic properties when administered less than two hours after eating are provided, and therapeutic uses thereof.
Type:
Application
Filed:
August 7, 2020
Publication date:
November 26, 2020
Inventors:
Julien Grassot, Cendrine Grangeon, Jordan Dubow
Abstract: Provided herein is a method of using threonate to alter cellular physiology, such as neuronal physiology. A method of the present disclosure may include providing to a medium comprising a cell, a threonate-containing compound, or a precursor thereof, to increase the concentration of threonate in the medium, where the increased concentration of threonate is sufficient to increase the concentration of magnesium in the cell. Also provided is a method that includes administering a threonate-containing compound, or a precursor thereof, to an individual, to increase synaptic density in the brain and/or to treat a neurological disorder, e.g., cognitive impairment. The threonate-containing compound of the present disclosure does not include magnesium threonate.
Abstract: Compositions with fulvate fractions alone or in combination with growth factors, bioactive fragmented peptides, or combinations thereof are disclosed herein. Also disclosed are methods of using said compositions for the catalyzing cellular regeneration, including the healing, treatment, or prevention of skin disorders. Also disclosed are methods for extracting, isolating, and purifying fulvate fractions for use in the manufacture of said compositions.
Type:
Application
Filed:
February 28, 2020
Publication date:
November 26, 2020
Inventors:
Gary W. Black, Jane Christensen, Farhan Taghizadeh
Abstract: Provided in some embodiments are methods of treating or preventing Raynaud's, comprising prescribing and/or administering to an individual in need thereof 2-(((1r,4r)-4-(((4-chlorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetic acid (Compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
Type:
Application
Filed:
August 7, 2018
Publication date:
November 26, 2020
Inventors:
John W. ADAMS, Christen M. ANDERSON, William R. SHANAHAN
Abstract: This document provides methods and materials for treating polycystic diseases such as polycystic kidney disease. For example, methods for using a TRPV2 agonist (e.g., probenecid) and optionally a vasopressin receptor antagonist (e.g., tolvaptan) to treat a mammal having polycystic kidney disease (e.g., autosomal dominant polycystic kidney disease) are provided.
Type:
Application
Filed:
December 6, 2018
Publication date:
November 26, 2020
Applicant:
Mayo Foundation for Medical Education and Research
Inventors:
Vicente E. Torres, Fouad T. Chebib, Peter C. Harris, Xiaofang Wang
Abstract: Disclosed herein are methods of for treating hyperammonemia in a patient having renal impairment, comprising administering carglumic acid to said patient at a reduced daily dosage.
Abstract: This disclosure relates to deuterated D-serine, pharmaceutically acceptable salts thereof, analogs and prodrugs thereof, pharmaceutical compositions thereof, and methods of use.
Type:
Application
Filed:
November 21, 2018
Publication date:
November 26, 2020
Inventors:
Dario Doller, Christopher L. Brummel, Julie F. Liu, Roger D. Tung
Abstract: The subject invention provides therapeutic compositions, and uses thereof for the treatment or amelioration of symptoms of a disease selected from the group consisting of: Ebola virus infection, HIV infection, ataxia, environmental enteropathy, cancer, hangover, inflammatory disease, and porcine epidemic diarrhea. In preferred embodiments, the composition includes a combination of one or more amino acids selected from the group comprising lysine, aspartic acid, glycine, isoleucine, threonine, tyrosine, valine, tryptophan, asparagine and/or serine.
Type:
Application
Filed:
August 7, 2020
Publication date:
November 26, 2020
Inventors:
Sadasivan VIDYASAGAR, Stephen J. GATTO, Daniel B. DENNISON
Abstract: The present invention includes surprisingly water-soluble salts of a phenylalkylamine compound that are potent antagonists of L-type calcium channels. Aqueous solutions including salts of the instant invention are formulated for nasal administration and provide a novel therapeutic platform for the treatment of stable angina, migraine, and cardiac arrhythmia, such as paroxysmal supraventricular tachycardia.
Abstract: Disclosed herein are methods of treating a tumor or cancer in a subject whose tumor or cancer cells express low levels of asparagine synthetase (ASNS), and compounds and compositions useful in such treatment. Also disclosed herein are methods of evaluating whether to administer a compound that inhibits glutathione production or a glutaminase inhibitor to a subject with a tumor or cancer.
Type:
Application
Filed:
June 3, 2020
Publication date:
November 26, 2020
Inventors:
Timothy HEFFERNAN, Jeffrey KOVACS, Nakia SPENCER, Christopher BRISTOW
Abstract: A pharmaceutical composition containing synthetic Cannabidiol and its use in obtaining a medication for the treatment of neurological disorders, as well as the main excipients used in the production process, in addition to its small, medium, and large-scale preparation process. The use of the composition for the treatment of neurological disorders in human or animal populations, in particular in the treatment of Parkinson's disease, in the range of 300 to 850 mg/day or at daily doses of 100 to 1750 mg for neuroprotective action.
Type:
Application
Filed:
February 11, 2019
Publication date:
November 26, 2020
Applicants:
Prati, Donaduzzi & Cia Ltda, Universidade De São Paulo
Inventors:
Luiz Donaduzzi, Carmen Maria Donaduzzi, Liberato Brum Junior, Patrícia Moura Da Rosa Zimmerman, Emanuelle Webler, Letícia Mello Rechia, José Alexandre Crippa, Jaime Eduardo Cecilio Hallak, Antonio Waldo Zuardi, Francisco Silveira Guimarães, Alline Cristina De Campos, Vitor Tumas, Elaine Aparecida Del Bel Belluz Guimarães
Abstract: The present invention relates to a method of increasing fertility, or reducing rate of decline in fertility, or restoring fertility, of a female subject, comprising administering to the subject an effective amount of an agent which elevates SIRT2 activity or SIRT2 expression, and to compositions and kits for increasing fertility, or reducing rate of decline in fertility, or restoring fertility.
Type:
Application
Filed:
July 31, 2018
Publication date:
November 26, 2020
Inventors:
Lindsay Edward Wu, David Andrew Sinclair, Hayden A. Homer
Abstract: A composition containing SUMO inhibitor, and belongs to the technical field of medicine includes FXR agonist and SUMO inhibitor. In activated hepatic stellate cells, the FXR agonist does not have an effect in inhibiting the activation of hepatic stellate cells. After the FXR agonist and the SUMO inhibitor are compounded according to the present invention, the activation of hepatic stellate cells can also be inhibited for those cells under activated state. Of note, the hepatic stellate cells of an individual with hepatic fibrosis symptoms have been in an activated state, therefore a good anti-fibrotic effect cannot be achieved by using the FXR agonist alone.
Abstract: Provided herein are stable enalapril oral liquid formulations. Also provided herein are methods of using enalapril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and asymptomatic left ventricular dysfunction.
Abstract: Methods of treating, managing or preventing diseases ameliorated by inhibiting PDE4 such as psoriasis, ankylosing spondylitis, Behcet's disease, rheumatoid arthritis, atopic dermatitis, Crohn's disease, and ulcerative colitis are disclosed. Specific methods encompass the administration of apremilast in specific dosage titration schedule, alone or in combination with a second active agent.
Abstract: The present invention relates to use of a carbonate compound of chemical formula 1, or a pharmaceutically permissible salt, solvate or hydrate thereof, for prevention, alleviation or treatment of visceralgia, or pain arising from visceral disease.
Abstract: Imidazole-based compounds as hepatitis C virus (HCV) inhibitors. The compounds have an imidazole core that is disubstituted via amide links. Also described are a pharmaceutical composition incorporating the imidazole-based compound, a method of preparing these compounds, and a method for using the pharmaceutical composition in the treatment of HCV infection.
Abstract: This invention relates to a method of treating cancer by administering to a patient in need thereof, over a period of time, therapeutic agents that consist essentially of a MEK inhibitor which is binimetinib or a pharmaceutically acceptable salt thereof, and a PD-1 binding antagonist, to a patient in need thereof.
Type:
Application
Filed:
January 10, 2018
Publication date:
November 26, 2020
Inventors:
Patrice A. LEE, David CHANTRY, Shannon L. WINSKI
Abstract: The present disclosure provides endosomal disruptors, which are useful for facilitating delivery of a macromolecule to the cytoplasm of a cell. The present disclosure provides compositions comprising an endosomal disruptor and a macromolecule. The present disclosure provides methods of delivering a macromolecule to the cytoplasm of a cell.
Type:
Application
Filed:
December 3, 2018
Publication date:
November 26, 2020
Inventors:
Niren Murthy, Joachim Justad Roeise, Chung Hak Taing
Abstract: Disclosed herein is a ganetespib-containing particle, which includes an active ingredient selected from ganetespib, a pharmaceutically acceptable salt of ganetespib, and a combination thereof, and an amphiphilic chitosan-based carrier carrying the active ingredient. Also disclosed herein are a pharmaceutical composition including the ganetespib-containing particle, and use of such pharmaceutical composition in treating cancer.
Abstract: Provided herein are protein translation inhibitors and pharmaceutical compositions thereof that bind to an RNA Recognition motif in heterogeneous ribonucleoprotein A18 to inhibit binding to mRNA transcripts thereby inhibiting protein synthesis. Also provided is a method for treating a cancer by administering a pharmaceutically acceptable amounts of at least one of the protein translation inhibitors.
Type:
Application
Filed:
May 20, 2020
Publication date:
November 26, 2020
Applicant:
University of Baltimore, Maryland
Inventors:
France Carrier, Alexander D. MacKerell, David J. Weber, Wenbo Yu
Abstract: A pramipexole transdermal patch for treatment of neurological disorders including Parkinson's disease that may be administered on a daily basis. The pramipexole transdermal patch of the present invention preferably comprises a drug-containing layer that comprises pramipexole or a pharmaceutically acceptable salt thereof at 2% to about 15% by weight of the drug—containing layer and at least two acrylic polymers wherein each polymer may further comprise carboxyl and/or hydroxyl functional groups. The pramipexole transdermal patch of the present invention may further comprise two or more permeation enhancers with combined pramipexole solubility of great than 50 mg/mL.
Abstract: The present disclosure relates to 3-substituted 1,2,4-oxadiazole compounds and their derivatives, which are useful as T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) inhibitors or as dual inhibitors of TIM-3 and the programmed cell death 1 (PD-1) signaling pathway. The disclosure also relates to treatment of disorders by inhibiting an immunosuppressive signal induced by TIM-3, PD-1, PD-L1, and/or PD-L2.
Type:
Application
Filed:
October 31, 2018
Publication date:
November 26, 2020
Inventors:
Pottayil Govindan N. Sasikumar, Muralidhara Ramachandra, Seetharamaiah Sethy S. Naremaddepalli, Nagaraj Gowda
Abstract: The present invention relates to compositions for the treatment of a malignant disease and in particular to compositions comprising an NF-?B inhibitor and a ?-glutamyltransferase (?-GT) inhibitor and therapeutic uses thereof. The invention further relates to in vitro methods of testing putative anti-tumour agents for their potential to act as therapeutically effective anti-tumour agents in vivo. Embodiments of the invention have been particularly developed for bringing NF-?B inhibitors to the clinic such as to provide alternative therapeutic options in the treatment of malignant diseases and will be described hereinafter with reference to this application. However, it will be appreciated that the invention is not limited to this particular field of use.
Abstract: Amorphous rifaximin, methods of making it, and pharmaceutical compositions containing it. Also described are methods of converting amorphous rifaximin to crystalline rifaximin and vice versa.
Abstract: The application describes treatment of hepatic encephalopathy using gastrointestinal specific antibiotics. One example of a gastrointestinal specific antibiotic is rifaximin.
Abstract: The present invention relates to a liquid, propellant-free pharmaceutical preparation and a method for administering a pharmaceutical preparation by nebulizing the pharmaceutical preparation in an inhaler. The propellant-free pharmaceutical preparation comprises: (a) an active substance selected from umeclidinium bromide and vilanterol trifenatate and combinations thereof; (b) a solvent; (c) a pharmacologically acceptable solubilizing agent; and (d) a pharmacologically acceptable preservative, and optionally includes a pharmacologically acceptable stabilizer, a pharmacologically acceptable co-solvent, or other pharmacologically acceptable additives.
Type:
Application
Filed:
May 22, 2020
Publication date:
November 26, 2020
Inventors:
Cai Gu Huang, Ying Ai Xu, Yue Zhao, Hui Yuan
Abstract: Disclosed are compositions including berberine combined with pea proteins and one or more surfactants. Also disclosed are processes for the preparation of the compositions, and the formulations and uses thereof.
Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.
Abstract: The present invention relates to agents and compositions for the modification of the growth of bacterial cells. Thus, the compounds of the present invention are useful for the prevention and/or treatment of a disease in a subject. In particular, the present invention relates to the field of repurposing pharmaceutical compounds for treatment strategies of infectious diseases, gastrointestinal disorders, inflammatory diseases, proliferative diseases, metabolic disorders, cardiovascular diseases, and immunological diseases. Some of the compounds of the present invention demonstrate high specificity in inhibiting the growth of single bacterial species. Such compounds enable narrow-spectrum antibacterial therapies, constituting a major effort of current and future drug development strategies in order to reduce side effects of antibacterial treatment plans.
Type:
Application
Filed:
February 13, 2019
Publication date:
November 26, 2020
Inventors:
MIHAELA PRUTEANU, LISA MAIER, MICHAEL KUHN, PEER BORK, ATHANASIOS TYPAS, KIRAN RAOSAHEB PATIL, GEORG ZELLER